Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fenbendazole is a broad-spectrum benzimidazole anthelmintic used primarily in veterinary medicine to treat gastrointestinal parasites such as roundworms, hookworms, whipworms, certain tapeworms (Taenia genus), pinworms, strongyles, and giardia in animals including dogs, cats (off-label), horses, cattle, goats, rabbits, sheep and laboratory rodents. Its mechanism of action involves binding to beta-tubulin in parasite cells and disrupting microtubule formation. This disruption impairs cell division and glucose uptake by the parasite—ultimately leading to energy depletion and death of the parasite. Fenbendazole is poorly absorbed orally so it acts mainly within the gut lumen[1][2][3][5][6]. It is not approved for human use but has been discussed anecdotally for potential anti-cancer effects; however there are no clinical trials supporting its use for cancer therapy in humans[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fenbendazole.